The US would be willing to share the vaccine against coronavirus with other countries, said the President of the United States Donald trump.
"This has never been done before. We are mass-producing vaccine candidates advance to the first day when she approves, she was immediately available to Americans. We'll probably have a lot of (the vaccine) to people around the world," said trump, speaking in North Carolina.
The main task - to come to the formation of immunity to the coronavirus not through disease, but by drug, the most long-lasting immunity is likely to be generated if the double vaccination, said Minister of health Michael Murashko.
"Now we come to the formation of immunity through the disease. We are trying to get the vaccine..., forming immune medicinal way," he told reporters.
The coronavirus vaccine, developed by scientists at Oxford University, has successfully passed the first phase of the test, announced on Monday the developers of the vaccine, published the results of testing in the British medical journal The Lancet.
In testing the vaccine, dubbed nCoV ChAdOx1-19, in the period from 23 April to 21 may was attended by 1077 people. Vaccination has led to the development of the subjects of the antibodies to COVID-19, said the authors.
American biotechnology company Moderna will begin clinical trials of a vaccine against coronavirus new type on July 27, reports CNBC, citing the database of the US government.
The trials will involve around 30 thousand volunteers. Everyone will get a dose of potential vaccines in the amount of 0,1 milligram, 29 days of injection will be repeated. Some participants will be vaccinated with the drug-placebo.
In Institute Gamalei hope that a vaccine for the coronavirus will go into circulation on 14 and 15 August, reported RIA Novosti Director of the centre of epidemiology and Microbiology them. Gamalei Alexander Ginzburg.
"Well, that's where number to 14-15 August, respectively, I hope, will go into circulation the small amount of vaccine that will be able to turn out," said Ginzburg.